Characterizing the unique endocytic organelle of Trypanosoma cruzi
Characterizing the unique endocytic organelle of Trypanosoma cruzi
批准号:
9808880
负责人:
RONALD DREW ETHERIDGE
金额:
$18.85万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-05-21 至 2021-04-30
关键词:
3-DimensionalAgeAmericasAmino AcidsBasic ScienceBeliefBiologyBiotinBlood CellsBovine Serum AlbuminCRISPR/Cas technologyCatabolismCell membraneCellsCellular StructuresCessation of lifeChagas DiseaseClinicalComplexConflict (Psychology)ConsumptionCytoplasmCytosolDiet HabitsDigestionDiseaseEatingEndocytosisEndoplasmic ReticulumEnsureEnvironmentEpitopesEtiologyFamilyGenesGeneticGleanGoalsGolgi ApparatusGrowthHarvestImmune systemInfectionInsect VectorsInsectaInvestigationKnock-outKnowledgeLabelLeishmaniaLifeLife Cycle StagesLigaseLysosomesMass Spectrum AnalysisMediatingMetabolic ControlMitochondriaMolecularMolecular AnalysisNutrientOrganellesParasitesParasitic infectionPathogenicityPopulations at RiskPositioning AttributeProliferatingProteinsResourcesRoleSpecificityStructureSurfaceTechniquesTechnologyTherapeuticTimeTransferrinTrypanosoma brucei bruceiTrypanosoma cruziTubular formationVesicleWorkacute infectionbasechronic infectionelectron tomographyexperimental studyextracellularfeedingfightingobligate intracellular parasiteparasitismpathogenpathogenic bacteriaprotein degradationreconstructiontooluptakevirtual
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The etiological agent of Chagas disease, Trypanosoma cruzi, is an obligate intracellular parasite that infects an
estimated 10 million people in the Americas, with an at-risk population of 70 million. While the acute infection
by the parasite is effectively controlled by the immune system, a chronic infection can persist for the lifetime of
the host. Despite its recognition as the highest impact parasitic infection of the Americas, Chagas disease
remains underreported, understudied and underfunded. Basic research into the biology of T. cruzi has been
previously hindered by a lack of efficient genetic tools, but the advent of CRISPR/Cas9 gene editing
technology has cleared the way for more in-depth molecular analyses. The primary interface between T. cruzi
and its mammalian hosts is at the level of the replicative intracellular amastigotes in the cytoplasm of infected
host cells. Trypanosoma cruzi is one of only a few protozoan pathogens that live and replicate directly in the
cytosol of nucleated cells. Of the (mostly bacterial) pathogens that can inhabit the host cytosol, many have
been shown to actively induce host cytosolic protein degradation in order to obtain energy and amino acids
which are normally limiting in the cytoplasm. A long-standing mystery is how T. cruzi is able to extract
necessary nutrients from this impoverished environment? Unlike other parasites, T. cruzi has the ability to
endocytose and digest host cytosolic material via a long tubular invagination (cytopharynx) starting at a surface
plasma membrane pore (cytostome). This structure, referred to here as the cytostome/cytopharynx or CSP
complex, is present only in replicating forms of the T. cruzi and disassembles during the transition to
trypomastigote stages. The CSP structure, which has been examined extensively using electron tomography
techniques, has resisted molecular analysis, as the protein components comprising it have remained elusive.
We have recently identified the first protein targeted solely to the CSP structure, CP1, and our preliminary work
has shown that this protein colocalizes with endocytosed cargo in the CSP. In this proposal, we will use CP1 to
carry out the first in-depth characterization of the T. cruzi CSP. We will fuse CP1 to the BioID biotin ligase and
perform proximity labeling of the CSP to identify its protein components. A selected subset of the identified
components will be validated by endogenous tagging and assessed for their role in parasite feeding, replication
and survival. Additionally, we will extend our analysis of the host cell components taken up in the CSP to
determine the selectively with respect to host proteins or organelles during intracellular amastigote replication.
Completion of this study will allow us to begin analyzing in detail a unique, but crucial, aspect of T. cruzi
parasitism which previously resisted in-depth investigation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the Mechanistic Basis for Phagotrophy in the Protozoan Trypanosoma cruzi (equipment supplement)
-
批准号:10799091
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2022
-
负责人:RONALD DREW ETHERIDGE
-
依托单位:
Elucidating the Mechanistic Basis for Phagotrophy in the Protozoan Trypansoma cruzi
-
批准号:10345248
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2022
-
负责人:RONALD DREW ETHERIDGE
-
依托单位:
Elucidating the Mechanistic Basis for Phagotrophy in the Protozoan Trypansoma cruzi
-
批准号:10630908
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2022
-
负责人:RONALD DREW ETHERIDGE
-
依托单位:
Elucidating the Role of Endocytosis Via the Cytostome in the Life Cycle of Trypanosoma cruzi
-
批准号:10414106
-
项目类别:
-
资助金额:$47.98万
-
财政年份:2021
-
负责人:RONALD DREW ETHERIDGE
-
依托单位:
Elucidating the Role of Endocytosis Via the Cytostome in the Life Cycle of Trypanosoma cruzi
-
批准号:10279960
-
项目类别:
-
资助金额:$47.98万
-
财政年份:2021
-
负责人:RONALD DREW ETHERIDGE
-
依托单位:
Elucidating the Role of Endocytosis Via the Cytostome in the Life Cycle of Trypanosoma cruzi
-
批准号:10626864
-
项目类别:
-
资助金额:$47.98万
-
财政年份:2021
-
负责人:RONALD DREW ETHERIDGE
-
依托单位:
CHARACTERIZATION OF ESSENTIAL RHOPTRY KINASES OF TOXOPLASMA GONDII
-
批准号:8202521
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2011
-
负责人:RONALD DREW ETHERIDGE
-
依托单位:
CHARACTERIZATION OF ESSENTIAL RHOPTRY KINASES OF TOXOPLASMA GONDII
-
批准号:8504684
-
项目类别:
-
资助金额:$5.39万
-
财政年份:2011
-
负责人:RONALD DREW ETHERIDGE
-
依托单位:
CHARACTERIZATION OF ESSENTIAL RHOPTRY KINASES OF TOXOPLASMA GONDII
-
批准号:8490510
-
项目类别:
-
资助金额:$5.22万
-
财政年份:2011
-
负责人:RONALD DREW ETHERIDGE
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: